HOMA-beta independently predicts survival in patients with advanced cancer on treatment with immune checkpoint inhibitors
Pre-ICI HOMA-beta level is linked to longer OS in ICI-treated patients. This connection is significant and shows that insulin secretory capacity may predict ICI efficacy.
Authors
- Mayu Watanabe (ORCID: https://orcid.org/0000-0003-4253-3465)
- Atsushi Takamoto (ORCID: https://orcid.org/0000-0002-1107-2291)
- Jun Eguchi (ORCID: https://orcid.org/0000-0003-2215-7343)
- Hiromitsu Kanzaki (ORCID: https://orcid.org/0000-0002-0545-8892)
- Jun Wada
- Syunsuke Kagawa
- Yohei Noda
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
- Fukuyama City Hospital (JP)
- Tsuyama Chuo Hospital (JP)
- Okayama Medical Center (JP)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3389/fendo.2024.1439705
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development